ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMGN ImmunoGen Inc

31.235
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
ImmunoGen Inc NASDAQ:IMGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 31.235 32.80 29.67 0 01:00:00

Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm

12/01/2024 4:10pm

PR Newswire (US)


ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more ImmunoGen Charts.

NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 

Kuehn Law, PLLC (PRNewsfoto/Kuehn Law, PLLC)

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: 

  • Pioneer Natural Resources (NYSE: PXD)

Pioneer Natural Resources has agreed to merge with Exxon Mobil. Under the proposed transaction Pioneer Natural Resources shareholders will receive $253.00 in cash per share.

  • ImmunoGen, Inc. (Nasdaq: IMGN)

ImmunoGen has agreed to be acquired by AbbVie for $31.26 per share in cash, amounting to an estimated total equity value of $10.1 billion.

  • Hawaiian Holdings, Inc. (Nasdaq: HA)

Hawaiian Holdings, Inc. has agreed to merge with Alaska Air Group. Under the agreement, shareholders of Hawaiian Airlines are set to receive $18.00 per share in cash, valuing the transaction at around $1.9 billion.

  • Icosavax, Inc. (Nasdaq: ICVX)

According to the agreement terms, AstraZeneca will, via a subsidiary, start a tender offer to purchase all outstanding shares of Icosavax for $15.00 per share in cash. Additionally, shareholders will receive a non-tradable contingent value right for up to $5.00 in cash.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.

How to Get Involved:

Kuehn Law is dedicated to safeguarding shareholder interests. Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at justin@kuehn.law or call (833) 672-0814. Kuehn Law covers all case costs and does not charge its investor clients. Shareholders are advised to act promptly, as legal rights may be time-sensitive.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-pxd-imgn-ha-and-icvx-investors-to-contact-law-firm-302033722.html

SOURCE Kuehn Law, PLLC

Copyright 2024 PR Newswire

1 Year ImmunoGen Chart

1 Year ImmunoGen Chart

1 Month ImmunoGen Chart

1 Month ImmunoGen Chart